Administration of recombinant NRG-1 is currently being tested as a novel therapy for reducing injury in myocardial infarction (ClinicalTrials.gov identifiers NCT01251406; NCT03388593) and soon to be tested in non-SCA stroke (https://news.ucr.edu/articles/2019/05/09/hope-horizon-treatingstroke). The gene discussed is NRG1; the disease is autosomal dominant cerebellar ataxia.